Humana (NYSE:HUM) Earns “Neutral” Rating from Cantor Fitzgerald

Cantor Fitzgerald restated their neutral rating on shares of Humana (NYSE:HUM) in a report released on Tuesday morning, Benzinga reports. Cantor Fitzgerald currently has a $395.00 target price on the insurance provider’s stock.

HUM has been the subject of a number of other research reports. Morgan Stanley initiated coverage on shares of Humana in a research note on Monday, June 24th. They set an equal weight rating and a $374.00 target price for the company. Oppenheimer lifted their target price on shares of Humana from $370.00 to $400.00 and gave the company an outperform rating in a research note on Thursday, August 1st. Piper Sandler initiated coverage on shares of Humana in a research note on Wednesday, June 26th. They set an overweight rating and a $392.00 target price for the company. Baird R W raised shares of Humana to a hold rating in a research note on Thursday, May 30th. Finally, Robert W. Baird initiated coverage on shares of Humana in a research note on Thursday, May 30th. They set a neutral rating and a $374.00 target price for the company. Thirteen investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Humana presently has a consensus rating of Hold and an average price target of $398.70.

Humana Trading Down 0.9 %

Humana stock opened at $321.56 on Tuesday. The company has a 50 day moving average price of $364.11 and a 200 day moving average price of $346.86. Humana has a 52 week low of $298.61 and a 52 week high of $530.54. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.66 and a current ratio of 1.66. The firm has a market capitalization of $38.72 billion, a price-to-earnings ratio of 20.02, a P/E/G ratio of 2.56 and a beta of 0.50.

Humana (NYSE:HUM) last posted its quarterly earnings data on Wednesday, July 31st. The insurance provider reported $6.96 EPS for the quarter, topping analysts’ consensus estimates of $5.89 by $1.07. Humana had a net margin of 1.53% and a return on equity of 16.12%. The firm had revenue of $29.54 billion during the quarter, compared to analyst estimates of $28.52 billion. During the same quarter last year, the business posted $8.94 EPS. The company’s revenue was up 10.4% on a year-over-year basis. Research analysts forecast that Humana will post 16 EPS for the current year.

Humana Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Shareholders of record on Monday, September 30th will be given a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a yield of 1.10%. The ex-dividend date of this dividend is Monday, September 30th. Humana’s dividend payout ratio is 22.04%.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Private Advisor Group LLC raised its position in shares of Humana by 15.0% during the fourth quarter. Private Advisor Group LLC now owns 3,339 shares of the insurance provider’s stock valued at $1,529,000 after buying an additional 436 shares during the last quarter. Principal Securities Inc. acquired a new position in shares of Humana during the fourth quarter valued at about $651,000. Cary Street Partners Investment Advisory LLC raised its position in shares of Humana by 23.9% during the fourth quarter. Cary Street Partners Investment Advisory LLC now owns 1,212 shares of the insurance provider’s stock valued at $555,000 after buying an additional 234 shares during the last quarter. Principal Financial Group Inc. raised its position in shares of Humana by 10.3% during the fourth quarter. Principal Financial Group Inc. now owns 159,907 shares of the insurance provider’s stock valued at $73,207,000 after buying an additional 14,997 shares during the last quarter. Finally, Ieq Capital LLC raised its position in shares of Humana by 12.3% during the fourth quarter. Ieq Capital LLC now owns 3,867 shares of the insurance provider’s stock valued at $1,770,000 after buying an additional 424 shares during the last quarter. Institutional investors and hedge funds own 92.38% of the company’s stock.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.